Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Total Current Liabilities (2022 - 2025)

Coya Therapeutics' Total Current Liabilities history spans 4 years, with the latest figure at $3.7 million for Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 58.13% year-over-year to $3.7 million; the TTM value through Sep 2025 reached $3.7 million, up 58.13%, while the annual FY2024 figure was $3.8 million, 24.3% down from the prior year.
  • Total Current Liabilities for Q3 2025 was $3.7 million at Coya Therapeutics, down from $4.5 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $5.1 million in Q4 2023 and bottomed at $1.2 million in Q2 2023.
  • The 4-year median for Total Current Liabilities is $3.8 million (2022), against an average of $3.3 million.
  • The largest YoY upside for Total Current Liabilities was 241.05% in 2024 against a maximum downside of 24.3% in 2024.
  • A 4-year view of Total Current Liabilities shows it stood at $3.8 million in 2022, then soared by 32.13% to $5.1 million in 2023, then dropped by 24.3% to $3.8 million in 2024, then decreased by 4.11% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for COYA's Total Current Liabilities are $3.7 million (Q3 2025), $4.5 million (Q2 2025), and $4.3 million (Q1 2025).